About
NexImmune is a biotechnology company developing antigen-directed immunotherapies using a proprietary AIM nanoparticle platform to program T cell responses for treatment of cancer, autoimmune, and infectious diseases.
Explore NexImmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.